Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 11.01 -0.42 (3.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.43 | 52 Week High | $9.23 | |||
| Open | $11.39 | 52 Week Low | $1.16 | |||
| Day High | $11.46 | P/E | N/A | |||
| Day Low | $10.99 | EPS | $-0.30 | |||
| Volume | 5,429,878 | |||||
